Results 281 to 290 of about 148,910 (315)
Some of the next articles are maybe not open access.
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2016
Metformin is the first choice among drugs used for the treatment of type II diabetes mellitus mainly because of several advantages: proven hypoglycemic effect, good safety profile, virtually no risk of hypoglycemia, body weight reduction, lipid-lowering effect, efficacy in preventing micro- and macrovascular complications as well as adverse cardiac and
Sessa C +5 more
openaire +2 more sources
Metformin is the first choice among drugs used for the treatment of type II diabetes mellitus mainly because of several advantages: proven hypoglycemic effect, good safety profile, virtually no risk of hypoglycemia, body weight reduction, lipid-lowering effect, efficacy in preventing micro- and macrovascular complications as well as adverse cardiac and
Sessa C +5 more
openaire +2 more sources
Rejuvenation Research, 2011
Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established. The goal of this review is to investigate the evidence
openaire +2 more sources
Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established. The goal of this review is to investigate the evidence
openaire +2 more sources
Diabetes Technology & Therapeutics, 2016
Ranjit, Unnikrishnan, Viswanathan, Mohan
openaire +2 more sources
Ranjit, Unnikrishnan, Viswanathan, Mohan
openaire +2 more sources